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WBC
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1. INTRODUCTION {#tid13407-sec-0005}
===============

The presentation and progression of infections in solid organ transplant recipients (SOT) differ from immunocompetent hosts, frequently with greater severity.[^1^](#tid13407-bib-0001){ref-type="ref"} The COVID‐19 pandemic due to SARS‐CoV‐2 has resulted in nearly 12 million documented cases worldwide. The severity of COVID‐19 in the general population ranges from minimally symptomatic to critical illness in a proportion of patients.[^2^](#tid13407-bib-0002){ref-type="ref"} Several risk factors for admission and for development of severe and critical disease have emerged including older age, gender, and various common comorbid conditions. Based on experience with viral respiratory infections in SOT, it was speculated that the clinical phenotype of COVID‐19 would be more severe in solid organ transplant recipients. However, the natural history of infection is undefined, and published literature on the manifestations of COVID‐19 in solid organ transplant recipients remains limited.[^3^](#tid13407-bib-0003){ref-type="ref"}, [^4^](#tid13407-bib-0004){ref-type="ref"}, [^5^](#tid13407-bib-0005){ref-type="ref"}, [^6^](#tid13407-bib-0006){ref-type="ref"}, [^7^](#tid13407-bib-0007){ref-type="ref"} To address some of these questions, we studied the progression of the disease in 52 solid organ transplant recipients by analyzing changes in their inflammatory markers and clinical progression over 3 weeks following the onset of symptoms.

2. METHODS {#tid13407-sec-0006}
==========

2.1. Data source and collection {#tid13407-sec-0007}
-------------------------------

We examined the medical records of all patients who tested positive at the Mass General Brigham healthcare system, a not‐for‐profit healthcare system affiliated with Harvard Medical School that includes 12 hospitals serving a third of the Massachusetts population. The Massachusetts General Hospital (MGH) and Brigham and Women\'s Hospital (BWH) are academic medical centers of the Mass General Brigham system in Boston, MA. Each centre performs solid organ transplantation of kidney, heart, lung, pancreas (MGH and BWH), and liver (MGH only). 446 transplants were performed in 2019 by the two programs. Over 8000 transplant recipients are followed in these centers.

We collected data from reporting functions of the integrated electronic health record used by all 12 hospitals of the Mass General Brigham network (Epic Systems). Data on all transplant recipients over 18 years of age that tested positive for COVID‐19 between February 1, 2020, and May 6, 2020, were included. Records were reviewed up to May 16, 2020, for follow‐up. This study was approved by the Mass General Brigham Institutional Review Board.

COVID‐19 was diagnosed if SARS‐CoV‐2 RNA was detected in clinical specimens (upper and/or lower respiratory tract specimens) by nucleic acid testing designated for emergency use authorization by the Food and Drug Administration and conducted in agreement with guidelines provided by the US Centers for Disease Control and Prevention.

2.2. Covariates {#tid13407-sec-0008}
---------------

We extracted baseline demographic data (age, gender, race, ethnicity, zip code), smoking status, comorbidities, medications at time of COVID‐19 diagnosis, SOT type and date, history of rejection within 3 months prior to COVID‐19 diagnosis. For patients admitted within the Mass General Brigham system, details of admission including presenting symptoms and vital signs, therapeutic drugs and strategies, clinical outcomes, serial clinical and laboratory parameters (complete blood count, CBC, creatinine, liver function tests, LFT, C‐reactive protein, procalcitonin, ferritin, D Dimer, IL‐6 level, hypersensitive troponin T, creatinine kinase, lactate dehydrogenase, LDH, and tacrolimus levels) through COVID‐19 illness.

2.3. Statistical analysis {#tid13407-sec-0009}
-------------------------

Comparison is made between patients admitted and those managed as outpatients. In addition, among those admitted to the hospital, comparison is made between those admitted to ICU at any point in their admission (ICU patients) and those managed exclusively in a non‐ICU, general medical/surgical setting (Non‐ICU patients). Statistical analysis was performed using Prism 8 (Version 8.4.2, GraphPad Software LLC) and Microsoft Excel (Version 16.16.21, Microsoft). Variables were compared using Fisher\'s exact test for categorical variables, Mann‐Whitney *U* test for non‐parametric continuous variables, single‐factor ANOVA for parametric categorical variables. Daily mean CRP, ferritin, D Dimer, and albumin were determined by averaging individual patient values over the next 3 days from collection for the period in which values were available for each patient to account for intermittent test acquisition in individual patients. Daily mean value was then obtained for all patients with values on the day of illness. ICU and non‐ICU daily means were compared. Graphs were prepared using Prism 8 (Version 8.4.2, GraphPad Software LLC). *P*‐value \<.05 was considered significant.

3. RESULTS {#tid13407-sec-0010}
==========

A total of 52 solid organ transplant recipients were identified as COVID‐19 positive with demographic data (Table [1](#tid13407-tbl-0001){ref-type="table"}). The median age was 58 years (IQR 50‐66), 34 (65%) were male. Median time from transplant was 43.5 months with a range of 4‐310 months, 12 (23%) were within 1 year of transplant. The majority were kidney transplant recipients (29, 56%) consistent with the population studied. Median body mass index (BMI) was 27.0 kg/m^2.^ 25 (48%) recipients were identified as white, 10 (19%) as Black, and 17 (33%) as Hispanic. Most recipients were immunosuppressed with tacrolimus, mycophenolate, and low‐dose corticosteroids. Only 1 recipient had experienced an episode of rejection within 3 months prior to COVID‐19 diagnosis. Hypertension (43 subjects, 83%), diabetes (35%), and chronic renal insufficiency were common comorbid conditions. Comparison between those admitted to any hospital (n = 40) vs those managed at home (n = 12) is shown in Table [1](#tid13407-tbl-0001){ref-type="table"}. Those admitted had a higher median age (61 years vs 50 years, *P* = .002) and were more likely to have a diagnosis of ischemic heart disease (12 vs 0, *P* = .047). Pre‐admission medications included a statin in 29 (53%) and ACE‐inhibitor or angiotensin II receptor blocker (ARB) in 7 (13%) and were not associated with admission or ICU care. No other baseline factors were associated with admission.

###### 

Demographic characteristics of SOT recipients diagnosed with COVID‐19, with comparison between those admitted and not admitted

  Characteristics                            All (%)      Admitted (%)   Not admitted (%)   *P*‐value
  ------------------------------------------ ------------ -------------- ------------------ -----------
  Number                                     52 (100%)    40 (77%)       12 (23%)           
  Median Age (IQR)                           58 (50‐66)   61 (52‐66)     50 (36‐53)         .002
  Male                                       34 (65%)     28 (70%)       6 (50%)            .202
  Organ                                                                                     
  Kidney                                     29 (56%)     22 (55%)       7 (58%)            .838
  Liver                                      9 (17%)      7 (18%)        2 (17%)            \>.99
  Heart                                      6 (12%)      5 (13%)        1 (8%)             .655
  Lung                                       6 (12%)      5 (13%)        1 (8%)             \>.99
  Multi‐organ                                2 (4%)       1 (13%)        1 (8%)             .412
  Median time from transplant (months)       43.5         45             33                 .962
  Range                                      4‐310        4‐298          5‐310              
  0‐3 mo                                     0            0              0                  
  3‐12 mo                                    12 (23%)     9 (23%)        3 (25%)            
  Baseline immunosuppression                                                                
  CNI                                        44 (85%)     34 (85%)       10 (83%)           
  Mycophenolate/Azathioprine                 38 (73%)     28 (70%)       10 (83%)           
  Prednisone                                 37 (71%)     29 (73%)       8 (67%)            
  Belatacept                                 5 (10%)      3 (8%)         2 (17%)            
  Sirolimus/Everolimus                       5 (10%)      4 (10%)        1 (8%)             
  Rejection in last 3 mo                     1 (2%)       1 (3%)         0 (0%)             
  Taking \>5 mg prednisone                   4 (8%)       3 (8%)         1 (8%)             
  Race/Ethnicity                                                                            
  White                                      25 (48%)     21 (53%)       4 (33%)            .329
  Black or African American                  10 (19%)     9 (23%)        1 (8%)             .42
  Hispanic                                   17 (33%)     10 (25%)       7 (58%)            
  Comorbidities                                                                             
  Hypertension                               43 (83%)     33 (83%)       10 (83%)           \>.99
  Diabetes mellitus                          18 (35%)     15 (38%)       3 (25%)            .508
  Chronic renal failure                      39 (75%)     30 (75%)       9 (75%)            \>.99
  Chronic lung disease                       9 (17%)      8 (20%)        1 (8%)             .666
  Asthma                                     3 (6%)       3 (8%)         0 (0%)             \>.99
  HIV                                        1 (2%)       1 (3%)         0 (0%)             \>.99
  Ischemic heart disease                     12 (23%)     12 (30%)       0 (0%)             .047
  Congestive cardiac failure                 10 (19%)     9 (23%)        1 (8%)             .42
  Hyperlipidemia                             16 (31%)     14 (35%)       2 (17%)            .301
  Active cancer                              1 (2%)       1 (3%)         0 (0%)             \>.99
  Current/former smoker                      23 (44%)     19 (48%)       4 (33%)            .513
  BMI (median) (kg/m^s^)                     27           27.1           25.1               .932
  Admission in Mass General Brigham System   32 (80%)                                       
  Admission OUTSIDE Mass General Brigham     8 (20%)                                        

Abbreviations: BMI, Body mass index; CNI, Calcineurin inhibitor (includes tacrolimus and cyclosporine).
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Forty patients were hospitalized, 32 were admitted within the Mass General Brigham system allowing detailed analysis of their admission. Indications for admission are summarized in Table [S1](#tid13407-sup-0001){ref-type="supplementary-material"}. Of 32 admitted patients, 11 patients received ICU care at any point in their admission (ICU patients) and 21 patients were managed exclusively in a non‐ICU setting (non‐ICU patients). Indications for admission are in Table [S1](#tid13407-sup-0001){ref-type="supplementary-material"}. Demographic characteristics for these patients are shown in Table [S2](#tid13407-sup-0001){ref-type="supplementary-material"}. Clinical characteristics at presentation are shown in Table [2](#tid13407-tbl-0002){ref-type="table"}. The need for supplemental oxygen on initial presentation was associated with admission to an ICU (11 vs 8, *P* = .001). Those admitted to an ICU had higher WBC (7.38 vs 5.09, *P* = .022), higher absolute neutrophil count (7.19 vs 4.3, *P* = .0056), higher aspartate transaminase (AST) (46 vs 26, *P* = .0028), higher alanine transaminase (ALT) (52 vs 22, *P* = .0024), higher lactate dehydrogenase (LDH) (383 vs 254, *P* = .024), higher C‐reactive protein (CRP) (120.4 vs 46.4, *P* = .0305), higher procalcitonin (0.51 vs 0.13, *P* = .0138), and higher creatinine kinase (CK)(159 vs 59.5, *P* = .0319) than those managed without ICU care.

###### 

Presenting characteristics of those hospitalized with comparison between those admitted to ICU at any point in their admission vs those never admitted to ICU (non‐ICU)

  Characteristic                                            Admitted (%)   ICU (%)       Non‐ICU (%)   *P*‐value
  --------------------------------------------------------- -------------- ------------- ------------- -----------
  N                                                         32 (100%)      11 (35%)      21 (65%)      
  Symptoms                                                                                             
  Fever                                                     24 (75%)       9 (82%)       15 (71%)      .681
  Dyspnea                                                   18 (56%)       8 (73%)       10 (48%)      .266
  Cough                                                     20 (63%)       7 (64%)       13 (62%)      \>.99
  Sore throat                                               3 (9%)         3 (27%)       0 (0%)        .033
  Myalgias                                                  13 (41%)       6 (55%)       7 (33%)       .283
  Fatigue                                                   19 (59%)       6 (55%)       13 (62%)      .687
  Nausea/vomiting                                           10 (31%)       4 (36%)       6 (29%)       .703
  Diarrhea                                                  9 (28%)        3 (27%)       6 (29%)       
  Chest pain                                                6 (19%)        4 (36%)       2 (10%)       .148
  Time course                                                                                          
  Symptom onset to test (median, days) (IQR)                3.5 (6)        2 (5)         4 (6)         .775
  Symptom onset to admission (median, days) (IQR)           7 (10)         5 (6)         7 (8)         .128
  Initial observations                                                                                 
  Febrile \>37.9                                            4 (13%)        2 (18%)       2 10%)        .593
  Supplemental O~2~ requirement on admission                12 (38%)       11 (100%)     8 (38%)       .001
  FiO~2~ range                                              24%‐100%       24%‐100%      24%‐44%       
  Chest x‐ray findings                                                                                 
  None                                                      10 (31%)       2 (18%)       8 (38%)       .425
  Unilateral                                                5 (16%)        1 (9%)        4 (19%)       .637
  Bilateral                                                 17 (53%)       8 (73%)       9 (43%)       .148
  Median initial laboratory results on presentation (IQR)                                              
  WBC (K/uL)                                                5.86 (3.4)     7.38 (7.3)    5.09 (3.41)   .022
  ANC (K/uL)                                                4.84 (3.5)     7.19 (6.85)   4.3 (2.92)    .006
  ALC (K/uL)                                                0.56 (0.47)    0.48 (0.58)   0.61 (0.43)   .152
  Creatinine (mg/dL)                                        1.45 (1.05)    1.96 (1.16)   1.43 (0.88)   .703
  AST (U/L)                                                 31 (22)        46 (29.25)    26 (15)       .003
  ALT (U/L)                                                 27 (19)        52 (44)       22 (12)       .002
  LDH (U/L)                                                 295 (147)      383 (254)     254 (111)     .024
  C‐reactive protein (mg/L)                                 60.7 (89)      120.4 (117)   46.4 (82)     .031
  Procalcitonin (ng/mL)                                     0.17 (0.35)    0.51 (4.51)   0.13 (0.13)   .014
  Ferritin (ug/L)                                           702 (2754)     1361 (2761)   686 (1818)    .212
  D Dimer (ng/mL)                                           1074 (1570)    1121 (1470)   978 (1547)    .470
  Troponin T (ng/L)                                         23 (41)        22.5 (41)     22 (50)       \>.99
  Creatinine kinase (U/L)                                   71 (76)        159 (199)     59.5 (60)     .032

Abbreviations: ALC, absolute lymphocyte count; ALT, Alanine transaminase; ANC, absolute neutrophil count; AST, Aspartate transaminase; ICU, intensive care unit; LDH, Lactate dehydrogenase; WBC, White blood cell count.
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3.1. Inpatient management {#tid13407-sec-0011}
-------------------------

Inpatient management is shown in Table [3](#tid13407-tbl-0003){ref-type="table"}. All of those admitted to ICU were intubated and required vasopressors (11, 100%); 8 (73%) required prone positioning and 5 (45%) required dialysis. Median time to ICU admission was 7 days from symptom onset. Only 12 (57%) of the non‐ICU patients required supplemental oxygen at some point in their hospitalization with 8 (38%) of these requiring supplemental oxygen on admission.

###### 

Features of inpatient management for hospitalized patients with comparison between those admitted to ICU at any point in their admission vs those never admitted to ICU (non‐ICU)

                                                All         ICU         Non‐ICU    *P*‐value
  --------------------------------------------- ----------- ----------- ---------- -----------
  N                                             32 (100%)   11(35%)     21 (65%)   
  Immunosuppression changes                                                        
  Proportion any IS changes                     22 (69%)    8 (73%)     14 (67%)   \>.999
  Pre‐admission Aza/MMF                         24          9           16         
  Aza/MMF held                                  12 (50%)    6 (67%)     6 (38%)    
  Aza/MMF halved                                7 (29%)     2 (22%)     5 (31%)    
  Pre‐admission CNI                             26          9           17         
  CNI held                                      1 (4%)      1 (11%)     0 (0%)     
  CNI started                                   1 (3%)      0 (0%)      1 (5%)     
  Pre‐admission MTOR                            3           0           3 (14%)    
  MTOR held                                     3 (100%)    0 (0%)      3 (100%)   
  Pre‐admission Belatacept                      3           2           1 (5%)     
  Belatacept held                               2 (67%)     2 (100%)    0 (0%)     
  Pre‐admission steroids                        25          9           16 (76%)   
  Steroids held                                 0 (0%)      0 (0%)      0 (0%)     
  Steroids increased                            4 (16%)     4 (44%)     0 (0%)     
  Other drugs                                                                      
  Antibiotics                                   20 (63%)    11 (100%)   9 (43%)    .002
  Hydroxychloroquine                            11 (34%)    6 (55%)     5 (24%)    .123
  Remdesivir                                    1 (3%)      0 (0%)      1 (5%)     \>.999
  Statin                                        22 (69%)    9 (82%)     13 (62%)   .425
  Tocilizumab                                   1 (3%)      0 (0%)      1 (5%)     \>.999
  Trial enrollment                              9 (28%)     3 (27%)     6 (29%)    .387
  Other management                                                                 
  Supplemental O~2~ required during admission   23 (72%)    11 (100%)   12 (57%)   .013
  Prone positioning                             9 (28%)     8 (73%)     1 (5%)     \<.001
  Vasopressors required                         11 (34%)    11 (100%)   ‐          \<.001
  Dialysis                                      5 (16%)     5 (45%)     1 (5%)     .011

Abbreviations: Aza, Azathioprine; CNI, calcineurin inhibitor; ICU, intensive care unit; IS, Immunosuppression; MMF, mycophenolate; MTOR, Mammalian target of rapamycin inhibitor.
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Antibiotics were more frequently given to ICU patients than non‐ICU patients (11 vs 9, *P* = .0021). Hydroxychloroquine was given to 11 patients (35%) including 6 (55%) admitted to ICU. Statins were given or continued in 21 (68%), off‐label tocilizumab was used in one patient, and nine patients (28%) were enrolled in therapeutic drug trials. Immunosuppression was changed in 22 (69%) of those admitted including 8 (73%) of the ICU patients and 14 (67%) of the non‐ICU patients. Of those on an antimetabolite (MMF or azathioprine), 19 (71%) had these drugs held (50%) or reduced by half (29%). Only one patient admitted to ICU on mycophenolate had no adjustment. Calcineurin inhibitors were held in one patient (4%), and mTOR inhibitors were held in 3 (100%) patients. Belatacept^TM^ was deferred in two of three patients on this agent. Steroids were not withdrawn in any patients; 4 (44%) patients in the ICU group had stress dose steroids, usually in conjunction with reduction in other agents. Median tacrolimus levels pre‐COVID diagnosis and during inpatient admission were not different between ICU and non‐ICU patients (Figure [S1](#tid13407-sup-0001){ref-type="supplementary-material"}).

3.2. Clinical outcomes {#tid13407-sec-0012}
----------------------

Co‐infections were more frequent in those admitted to ICU compared to non‐ICU patients (5 vs 1, *P* = .037) (Table [4](#tid13407-tbl-0004){ref-type="table"}). The most common proven co‐infections were pulmonary infections including ventilator‐associated pneumonia (2, 18%) and fungal infection (1 *Aspergillus versicolor*, one patient had severe cutaneous candidiasis). Suspected co‐infection occurred in 4 (36%) of ICU patients and 3 (15%) non‐ICU patients. There were only two episodes of suspected rejection, both occurring in liver transplant recipients who had immunosuppression reduced during severe COVID‐19 in the ICU; tacrolimus levels in these patients were between 2 and 4 ug/mL at the time of suspected rejection. Deranged LFTs resolved with increased tacrolimus to baseline levels and re‐addition of mycophenolate mofetil.

###### 

Outcomes of hospitalized patients with comparison between those admitted to ICU at any point in their admission vs those never admitted to ICU (non‐ICU)

                             All         ICU        Non‐ICU    *P*‐value
  -------------------------- ----------- ---------- ---------- -----------
  N                          32 (100%)   11 (35%)   21 (65%)   
  Co‐infections                                                
  Proven co‐infection        6 (19%)     5 (45%)    1 (5%)     .037
  VAP                        2 (6%)      2 (18%)    0 (0%)     
  UTI                        1 (3%)      1 (9%)     1 (5%)     
  Fungal infection           2 (6%)      2 (18%)    0 (0%)     
  Suspected co‐infection     7 (22%)     4 (36%)    3 (14%)    .197
  Pneumonia                  5 (16%)     2 (18%)    3 (14%)    
  Bacteraemia                2 (6%)      2 (18%)    0 (0%)     
  Graft outcomes                                               
  Episode of rejection       2 (6%)      2 (18%)    0 (0%)     .1109
  Suspected                  2 (6%)      2 (18%)    0 (0%)     
  Proven                     0 (0%)      0 (0%)     0 (0%)     
  Patient outcomes                                             
  Discharged                 23 (72%)    3 (27%)    20 (95%)   \<.001
  Remain inpatient           4 (13%)     4 (36%)    0 (0%)     
  Remain in ICU, intubated   2 (6%)      2 (18%)    0 (0%)     
  Died                       5 (16%)     4 (36%)    1 (5%)     .037

Abbreviations: ICU, intensive care unit; UTI, urinary tract infection; VAP, ventilator‐associated pneumonia.
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Supplemental oxygen requirements increased for both ICU and non‐ICU patients after admission, peaking at day 6 of symptoms with mean FiO~2~ of 56% among ICU patients (Figure [S2](#tid13407-sup-0001){ref-type="supplementary-material"}). Inpatient dialysis was required in five patients; one was on dialysis prior to admission, two were kidney transplant recipients.

Mean laboratory values during hospitalization are shown in Figure [1](#tid13407-fig-0001){ref-type="fig"} from the day from symptom onset; each daily value is presented as an average over 3 days to account for alternate day testing in some patients. Both the ICU and non‐ICU patients have similar admission WBC, ALC, ferritin, CRP, D Dimer and albumin. Over time, WBC, ANC, CRP, ferritin, and D Dimer trended higher in those admitted to the ICU compared to the non‐ICU group, while albumin trended lower in those admitted to ICU compared to the non‐ICU group. Comparison of mean daily WBC, CRP, Ferritin D Dimer demonstrates higher levels overall in ICU vs non‐ICU patients (*P* \< .0001) but not ALC (*P* = .991), while mean daily albumin is lower in ICU vs non‐ICU patients (*P* \< .0001).

![Mean daily laboratory results for first 20 d of illness since symptom onset. Mean daily WBC (panel A), ALC (panel B), CRP (panel C), Ferritin (panel D), D Dimer (panel E) and albumin (panel E) in ICU (black line) vs non‐ICU (dashed line) group, with mean day of ICU admission demonstrated by black arrow (7 d). For each group, daily values of CRP, ferritin, D Dimer, and albumin are averaged over 3 d for each individual patient to account for alternate day testing. ICU, intensive care unit, WBC, white blood cell count, ALC, absolute lymphocyte count, CRP, C‐reactive protein. Mean daily WBC, CRP, ferritin and D Dimer are higher in the ICU group than Non‐ICU group (*P* \< .0001). Mean daily albumin is lower in the ICu group vs the non‐ICU group (*P* \< .001). There is no difference in mean daily ALC between the ICU and non‐ICU group (*P* = .991). ICU, intensive care unit; WBC, white blood cell count; ALC, absolute lymphocyte count; CRP, C‐reactive protein](TID-9999-e13407-g001){#tid13407-fig-0001}

WBC increased in ICU patients by day 2 and peaked by day 17 with a mean of 19.06 c/ul ± 16.67 before decreasing (Figure [S2](#tid13407-sup-0001){ref-type="supplementary-material"}). In contrast, most patients remained lymphopenic throughout their hospital stay; absolute lymphocyte counts gradually increased throughout hospitalization (Figure [S2](#tid13407-sup-0001){ref-type="supplementary-material"}). CRP levels started increasing early in the disease course peaking by day 13 in ICU patients (mean 196.3 mg/L ± 54.3) and at day 4 in non‐ICU patients (mean 141.9 mg/L ± 89) (Figure [S2](#tid13407-sup-0001){ref-type="supplementary-material"}). Ferritin and D Dimer levels continuously increased throughout admission and peaked by days 19 and 15 (peak mean ferritin 5356 ± SD 3564, peak mean D Dimer 5169 ± SD 3055 (Figure [S2](#tid13407-sup-0001){ref-type="supplementary-material"}).

With 10‐28 days of follow‐up, all but 4 (13%) patients have been discharged or died. 23 (72%) patients have been discharged without subsequent readmissions for COVID‐19 or other complications. Five (16%) patients have died, 4 (36%) of the ICU group and 1(5%) of the non‐ICU group who requested comfort measures. Two ICU patients remain intubated in the ICU, 2 ICU patients have improved and transferred to general medical care. All non‐ICU patients have been discharged or died.

4. DISCUSSION {#tid13407-sec-0013}
=============

The impact of COVID‐19 infections in immunosuppressed hosts remains to be defined. Our series of solid organ transplant recipients with documented COVID‐19 demonstrates a hospitalization rate of 77% and an ICU admission rate of 35%. Such rates are higher than the general population of COVID‐19 patients in our hospitals where admission rates are 28.6% and ICU admission is 9.4% (manuscript under consideration). These rates are also higher than the reported rates of hospitalizations and ICU admission in other published studies.[^8^](#tid13407-bib-0008){ref-type="ref"}, [^9^](#tid13407-bib-0009){ref-type="ref"} These heightened hospitalization and ICU admission rates suggest a potential adverse impact of immunosuppression. In support of this possibility, mechanical ventilatory support is required in about 12.2% of the general population admitted with COVID‐19,[^8^](#tid13407-bib-0008){ref-type="ref"} while our SOT cohort has almost 3 times this rate (35%). Furthermore, ICU level care is associated with death in 36% in our cohort, while a further 18% remain intubated in the ICU at time of last follow‐up. Overall mortality in our cohort was 16%, much higher than the overall mortality rate for all COVID‐19 patients in our system (4.3%, manuscript under consideration) and higher than the reported rates in the general population of 1%‐5%.[^10^](#tid13407-bib-0010){ref-type="ref"} Similar cohorts of SOT recipients have reported mortality rates between 24%‐28% overall and 52%‐64% in ICU patients.[^4^](#tid13407-bib-0004){ref-type="ref"}, [^5^](#tid13407-bib-0005){ref-type="ref"}, [^6^](#tid13407-bib-0006){ref-type="ref"} Our mortality rate is likely lower than these cohorts as we did not face resource limitations, and our hospitals had more time to prepare for COVID‐related admissions than other sites and the presence of demographic differences. Consistent with prior observations of risk factors for greater disease severity,,[^2^](#tid13407-bib-0002){ref-type="ref"}, [^8^](#tid13407-bib-0008){ref-type="ref"} those admitted in our cohort were more likely to be older and have ischemic heart disease. No association was found with other previously implicated associated comorbidities in our cohort, such as hypertension and diabetes, potentially due to small sample size and overall very high frequency of comorbidities in the transplant population.

The optimal management of immunosuppression in COVID‐19 infection is complicated by the intensity of the hyperinflammatory state that appears to contribute to the development of acute respiratory distress syndrome (ARDS), multi‐organ failure, and death. Our data suggest immunosuppressed SOT recipients are not protected from this phenomenon and may be more prone to systemic injury. In this series, immunosuppression was frequently reduced in the setting of documented COVID‐19 infection (69%), yet episodes of suspected rejection were rare. There were two episodes of suspected rejection in liver transplant recipients during the recovery phase of COVID‐19; LFTs normalized with re‐established immunosuppression. However, neither patient had a biopsy to confirm this. This data are also limited by the difficulty in recognizing rejection in heart and lung recipients and the potential that acute kidney injury in renal transplant recipients was not recognized as rejection. The overall rate of co‐infection was low; this observation may allow the judicious use of immunomodulatory therapies for systemic inflammation in transplant recipients; larger, prospective series are needed.

Our analysis demonstrates several trends in laboratory parameters for this group of patients. A biphasic pattern for inflammatory markers distinguished patients at risk for critical illness. At presentation, SOT recipients appear little different from other hosts with moderately elevated WBC, CRP, Ferritin, and D Dimer values. The requirement for supplemental oxygen, higher WBC and ANC, greater elevation of liver function tests, LDH, CRP, procalcitonin, and creatinine kinase (CK) are associated with the need for ICU care. Patients ultimately admitted to the ICU after day 5 developed continued elevation in WBC, CRP, and ferritin possibly reflecting the inflammatory state of severe COVID‐19 like that of non‐immunocompromised patients. It remains unknown, however, whether reductions in immunosuppression are protective or detrimental. Additional studies are needed.

In addition to the strengths discussed above and the large detailed sample with serial laboratory results and outcomes, our series has some limitations. These include the retrospective nature of the study, reliance on medical records and the relative under‐representation of heart and lung recipients in our cohort. Similarly, we do not have a direct comparison of non‐immunocompromised cohorts with which to compare out data to determine if immunosuppression is the true cause of heightened admission, ICU admission, and mortality rates. Subsequent studies will define the duration of viral shedding in SOT, the incidence and duration of SARS‐CoV‐2 viremia, as well as the biologic basis of the observed biphasic inflammatory response. The roles of immunosuppression, age, comorbidities, and other factors in the progression of COVID‐19 infection require additional studies.

Our data show that a significant proportion of admitted SOT patients require ICU care with high mortality. Close follow‐up and a relatively low threshold for hospitalization may be beneficial in SOT given the lack of predictors for deterioration at admission.
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